Bulbar ALS: Symptoms and Management Strategies

Key Symptoms Patients Experience in Bulbar ALS and What to Monitor

Speech changes and dysarthria: How bulbar ALS affects communication

Dysarthria -- difficulty articulating words due to weakened muscles of the tongue, lips, jaw, and voice box -- affects more than 80% of people with ALS at some point during the disease. [7] In bulbar-onset ALS specifically, speech changes can begin up to three years before a formal diagnosis, making them one of the earliest and most recognizable signs. [8] Because ALS damages both upper and lower motor neurons, most people develop mixed dysarthria: a combination of slurred, strained speech from upper motor neuron involvement and a breathy, nasal quality from lower motor neuron degeneration. [7] Research shows that people with bulbar-onset ALS typically experience significant reductions in speaking rate within 23 months of first symptoms, with speech becoming difficult to understand by 32 months -- compared to 60 months for those with limb-onset ALS. [7]

Swallowing difficulties and aspiration risks: Managing nutrition safely

Dysphagia affects up to 85% of people with ALS, resulting from degeneration of the cortical motor neurons and brainstem nuclei that coordinate swallowing. [10] Malnutrition affects between 16% and 55% of patients, and poor nutritional status at diagnosis is associated with higher mortality. [9] Mechanically altered diets -- pureed foods, minced textures, and thickened liquids -- reduce chewing demand and lower the risk of aspiration. [10] When oral intake can no longer meet nutrition needs, a gastrostomy tube (G-tube) offers consistent delivery of nutrition, hydration, and medications, and is generally recommended while lung function remains above 50% of predicted capacity to reduce procedural risk. [10]

Drooling, throat clearing, and pseudobulbar affect: Addressing quality-of-life concerns

Three symptoms that most affect daily dignity in bulbar ALS -- drooling, thick secretions, and pseudobulbar affect -- all have targeted management options. Up to 70% of people with ALS experience sialorrhea, which also raises aspiration pneumonia risk; botulinum toxin B injections into the parotid and submandibular glands are the guideline-recommended approach for refractory cases, with transdermal scopolamine or anticholinergic medications as alternatives. [11] Thick mucous secretions, often a sign of dehydration, can improve with increased fluid intake, N-acetylcysteine, and [mechanical cough-assist devices](https://alsunited.org/blog/cough-assist-machine/) when cough pressure is weak. [12] Pseudobulbar affect -- involuntary laughing or crying unrelated to actual mood -- affects 20% to 50% of patients and is treated with dextromethorphan/quinidine (DM/Q), the only FDA-approved medication for this symptom, or off-label antidepressants like amitriptyline. [11]

Evidence-Based Treatment and Management Strategies Patients Seek Most

Medication options: FDA-approved treatments and symptom management approaches

Three FDA-approved disease-modifying treatments exist for ALS -- riluzole, edaravone, and sodium phenylbutyrate/taurursodiol (PB/TURSO) -- each targeting a different pathway of motor neuron damage, as described in our [overview of ALS medication mechanisms](https://alsunited.org/blog/mechanisms-of-als-medications). [11] Riluzole reduces glutamate excitotoxicity and extends survival by approximately two to three months; guidelines from the American Academy of Neurology recommend offering it to every patient as early as possible after diagnosis. [13] Edaravone, available as an oral suspension or IV infusion, slowed functional decline by 33% at six months in a defined subset of early-stage patients. [11] PB/TURSO, approved in September 2022, reduces cellular and mitochondrial stress and extended median tracheostomy-free survival by 7.3 months in trials, while tofersen received accelerated FDA approval for the narrower group of patients whose ALS is linked to an SOD1 gene mutation. [11]

Speech-language pathology and swallowing therapy: Preserving communication and nutrition

Speech-language pathologists use a staged approach in bulbar ALS: early therapy focuses on breathing pacing and relaxation exercises to use respiratory resources efficiently, since forcing voice and articulation worsens intelligibility rather than improving it. [14] Optimizing body position reduces muscle tone and respiratory effort during speech, and eliminating background noise further improves communication clarity. [14] When speaking rate falls below 100 words per minute -- a threshold linked to significant intelligibility loss -- SLPs introduce augmentative and alternative communication (AAC) devices, from simple alphabet boards to electronic systems operated by eye movement. [14] Recording voice patterns before dysarthria becomes severe allows AAC devices to be programmed with the patient's own voice rather than a synthetic one, making the transition to assisted communication more personal and easier to accept. [14]

Multidisciplinary care teams: Why coordinated support delivers better outcomes

Multidisciplinary care -- coordinating a neurologist, pulmonologist, speech-language pathologist, dietitian, and palliative care team in a single visit -- reduces 1-year mortality by up to 30%, lowers hospitalization rates, and improves quality-of-life outcomes compared to general neurology care. [15] A four-year observational study found that patients in a structured multidisciplinary program reached a median survival of 50 months from symptom onset, above the 27-44 months reported in comparable studies. [16] For bulbar-onset ALS, this coordination matters early: same-day specialist access allows teams to initiate noninvasive ventilation electively in 89% of cases rather than waiting for a respiratory crisis. [16] Despite the evidence, only about 40% of people with ALS in the United States receive this level of care, with nearly 45% living more than 50 miles from the nearest clinic -- knowing [which specialists make up an ALS care team](https://alsunited.org/blog/what-type-of-doctor-treats-als-understanding-als-medical-care) is a practical starting point. [15]

Building Your Bulbar ALS Management Plan: A Patient-Centered Essentials and Next Steps

Essential questions to ask your care team at each stage

At each clinic visit, asking specific questions gives you more control over timing and decisions that are easier to make proactively than under pressure. Early on, ask your neurologist about disease-modifying treatment eligibility, open clinical trials, and the right time to begin voice banking before speech changes significantly. [17] As the disease progresses, ask your speech-language pathologist at what point to order an AAC device, and ask your pulmonologist which FVC threshold they use to initiate noninvasive ventilation -- typically below 50% of predicted capacity. [17] Consulting your multidisciplinary team before significant health decisions, including feeding tube placement and ventilation, helps ensure those choices reflect your values and priorities while more options remain available. [18]

How ALS United's clinic finder and support network connects you to specialized care

The average time from symptom onset to a first appointment at a multidisciplinary ALS clinic in the United States is 19 months, a delay that allows disease progression to outpace early intervention. [15] Our clinic finder links patients and caregivers to accredited centers meeting American Academy of Neurology practice standards, shortening the search at a point when time matters. [15] For those who can't travel to an in-person clinic, telehealth consultations from comprehensive ALS centers can reach patients at regional and community facilities, extending access without adding travel burden. [15] Our support network -- including [virtual support groups](https://alsunited.org/blog/join-a-support-group), care coordination, and equipment loan resources provided by an ALS Care Manager -- fills the gaps between clinic visits so you are never navigating this alone. [19]

Creating a communication and nutrition plan before symptoms advance

Creating a communication and nutrition plan before symptoms significantly advance protects your ability to make decisions while speech is still clear and swallowing is stable. Early advance care planning preserves patient autonomy, since worsening dysarthria or cognitive changes can limit your participation in these discussions as the disease progresses. [20] A feeding tube doesn't require stopping oral eating -- you can continue eating for pleasure while the tube meets nutritional needs -- and tube feeding is not a barrier to hospice enrollment. [20] These conversations should be revisited at each clinic visit so that plans continue to reflect your values and priorities over time. [21]